Phase II study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapy

Karl D. Lewis, Anjali Narwal, Elizabeth Stankevich et al.|Annals of Oncology|2018

Cited by 3